Plasma concentration of Ropivacain and Ketorolac after local infiltration during surgery in hip replacement during the first 24 postoperative hours.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-005471-10-SE

Enrollment

Registered

2008-09-05

Start date

2009-06-17

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain after surgery for hip replacement. MedDRA version: 9.1 Level: LLT Classification code 10044088 Term: Total hip replacement

Interventions

Trade Name: Narop Product Name: NaropNO1B09 Pharmaceutical Form: Solution for injection Trade Name: Toradol Product Name: Toradol Pharmaceutical Form: Injection* Trade Name: Adrenalin Product Name:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult males or females ASA 1-3 undergoing spinal anesthesia for elective hip replacement. After signed informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy for NSAID or local anesthetic, psychiatric disorder, demens, AV-block III, cardiac disorders, ulcus ventriculi and duodeni, renal disorders, coagulation disorder and patients who refuses to participate.

Design outcomes

Primary

Measure	Time frame
Main Objective: Plasmaconcentration of ropivacain (Narop) and ketorolac (Toradol) and its pharmacokinetict the first 24 hours after surgery for hip replacement;Secondary Objective: ;Primary end point(s):	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026